ARCHIVES

Also in this issue: ODAC Votes To Strip Breast Cancer Indication From Avastin

This article is from The Cancer Letter archive.

Vol. 36 No. 28 | July 23, 2010

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Karen Antman recruited to NCI on an IPA to oversee changes to centers, SPORE programs.

October 31, 2003

Cediranib Demonstates Control In Alveolar Soft Part Sarcoma

May 31, 2013

OMB Cut $150 Million From NCI Request

March 22, 1974

Asks BSC For Advice On Centers Funding, Other Pressing Issues, But Doesn’t Get Any

March 30, 1990

FDA Relies on Importation, Fast Approval, and Early Reporting to Combat Drug Shortages

February 24, 2012